AbbVie 2014 Annual Report Download - page 35

13NOV201221352027
ITEM 5. MARKET FOR REGISTRANT’s COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
ISSUER PURCHASES OF EQUITY SECURITIES
.....................................................................................................................................................................................................................................................................................................................................................
Principal Market
The principal market for AbbVie’s common stock is the New York Stock Exchange (NYSE). A
‘‘when-issued’’ trading market for AbbVie’s common stock began on the NYSE on December 10, 2012, and
‘‘regular way’’ trading of AbbVie’s common stock began on January 2, 2013. Prior to December 10, 2012
there was no public market for AbbVie’s common stock. AbbVie’s common stock is also listed on the
Chicago Stock Exchange and traded on various regional and electronic exchanges. Outside the United States,
AbbVie’s common stock is listed on NYSE Euronext Paris and the SIX Swiss Exchange.
Market Price Per Share
2014 2013
high low high low
First Quarter $54.73 $46.42 $40.80 $33.33
Second Quarter 56.90 45.50 48.00 39.96
Third Quarter 60.02 51.37 48.42 41.07
Fourth Quarter 70.76 52.06 54.78 44.32
Stockholders
There were 56,161 stockholders of record of AbbVie common stock as of January 31, 2015.
Dividends
Four quarterly dividends were paid on common stock in 2014. The first quarter cash dividend of $0.40
per share was payable February 14, 2014 and the second, third and fourth quarter dividends of $0.42 per
share were payable May 15, 2014, August 15, 2014 and November 17, 2014, respectively. On October 20,
2014, AbbVie’s board of directors declared an increase in the quarterly cash dividend from $0.42 per share
to $0.49 per share, payable on February 13, 2015 to stockholders of record as of January 15, 2015. A
quarterly dividend of $0.40 per share was paid on common stock in 2013. The timing, declaration, amount
of, and payment of any dividends by AbbVie in the future is within the discretion of its board of directors
and will depend upon many factors, including AbbVie’s financial condition, earnings, capital requirements of
its operating subsidiaries, covenants associated with certain of AbbVie’s debt service obligations, legal
requirements, regulatory constraints, industry practice, ability to access capital markets, and other factors
deemed relevant by its board of directors. Moreover, if AbbVie determines to pay any dividend in the
future, there can be no assurance that it will continue to pay such dividends or the amount of such
dividends.
AbbVie Inc. is an Illinois High Impact Business (HIB) and is located in a federal Foreign Trade Sub-Zone
(Sub-Zone 22S). Dividends may be eligible for a subtraction from base income for Illinois income tax
purposes. If you have questions, please contact your tax advisor.
Performance Graph
The following graph compares the cumulative total returns of AbbVie, the S&P 500 Index and the NYSE
Arca Pharmaceuticals Index. This graph covers the period from January 2, 2013 (the first day AbbVie’s
common stock began ‘‘regular-way’’ trading on the NYSE) through December 31, 2014. This graph assumes
$100 was invested in the stock or the index on January 2, 2013 and also assumes the reinvestment of
dividends. The stock price performance on the following graph is not necessarily indicative of future stock
price performance.
2014 Form 10-K 29
PART II